In 2014 it was approved for use in combination with trametinib (MEK1/2 inhibitor) which was also FDA-approved in 2013 to treat patients with unresectable or metastatic melanoma with a BRAF V600E/K mutation. The gene discussed is BRAF; the disease is metastatic melanoma.